School of Physics and Technology, Nantong University, No. 9, Seyuan Road, Nantong, Jiangsu 226019, P. R. China.
State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Research Center for Innovative Technology of Pharmaceutical Analysis, College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang 150081, P. R. China.
Anal Chem. 2024 Oct 1;96(39):15735-15745. doi: 10.1021/acs.analchem.4c03467. Epub 2024 Sep 16.
In the realm of disease diagnostics, particularly for conditions such as proteinuria and hemoglobinuria, the quest for a method that combines accurate, label-free detection of protein compositions and their conformational changes remains a formidable challenge. In this study, we introduce an innovative Ag/Au plasmonic hybrid coupling nanoarray (Ag/Au PHCN) architecture marked by sub-10 nm interparticle gaps. These nanoarrays, leveraging plasmonic hybrid coupling and synergistic enhancement mechanisms, create a plethora of uniform surface-enhanced Raman spectroscopy (SERS) hotspots. The Ag/Au PHCN substrates demonstrated unparalleled sensitivity in the unmarked detection of hemoglobin (HGB), bovine serum albumin (BSA), and cytochrome C (Cyt.C) in bodily fluids, incorporating the advantages of high sensitivity, high reproducibility, durability, recyclability, and biocompatibility. Notably, the detection limits for BSA and HGB are unprecedented at 0.5 and 5 ng/mL, respectively. This achievement sets a new benchmark for label-free protein detection using two-dimensional nanostructures. Crucially, the Ag/Au PHCNs possess the novel capability to discern protein conformational changes post denaturation, underscoring their potential in probing protein functionalities. Most importantly, these nanoarrays can differentiate between normal and proteinuria-affected urine samples and monitor protein content variations over time, heralding a new era in clinical diagnostics with particular relevance to proteinuria and hemoglobinuria detection.
在疾病诊断领域,特别是对于蛋白尿和血红蛋白尿等病症,寻找一种能够准确、无标记地检测蛋白质组成及其构象变化的方法仍然是一项艰巨的挑战。在本研究中,我们引入了一种创新的 Ag/Au 等离子体杂化耦合纳米阵列(Ag/Au PHCN)结构,其特点是亚 10nm 的粒子间间隙。这些纳米阵列利用等离子体杂化耦合和协同增强机制,创造了大量均匀的表面增强拉曼光谱(SERS)热点。Ag/Au PHCN 基底在体液中对血红蛋白(HGB)、牛血清白蛋白(BSA)和细胞色素 C(Cyt.C)的无标记检测中表现出无与伦比的灵敏度,结合了高灵敏度、高重现性、耐用性、可回收性和生物相容性的优点。值得注意的是,BSA 和 HGB 的检测限分别达到了前所未有的 0.5 和 5ng/mL。这一成就为使用二维纳米结构进行无标记蛋白质检测设定了新的基准。至关重要的是,Ag/Au PHCN 具有在蛋白质变性后辨别蛋白质构象变化的新能力,突显了其在探测蛋白质功能方面的潜力。最重要的是,这些纳米阵列能够区分正常尿液和蛋白尿尿液样本,并监测随时间的蛋白质含量变化,为临床诊断带来了一个新时代,特别是在蛋白尿和血红蛋白尿检测方面。